It is conceivable that the fusion WT NVs platform can be extended to concurrently targeting to other checkpoints for synergetic cancer immunotherapy except PD‐1/PD‐L1 and SIRPα/CD47, such as CTLA‐4, LAG‐3, TIGIT and so on (Kubli et al., 2021; Rudd et al., 2009; Yu et al., 2009). The gene discussed is TIGIT; the disease is cancer.